Navigation Links
Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2007 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, presented data from its experimental infection study at the 2007 Pediatric Academic Societies' (PAS) Annual Meeting being held in Toronto. This study represents an important component of the company's clinical development program for ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. Results demonstrated the establishment of a safe and reliable RSV infection in the upper respiratory tract of adult volunteers and as a result of this achievement, the company expects to begin a Phase II study evaluating the safety and efficacy of ALN-RSV01 in experimentally infected adults in the second quarter of this year.

The experimental infection model was designed to evaluate viral infectivity of RSV administered intranasally in healthy adult volunteers. Top-line data are summarized as follows:

-- A total of 36 subjects were exposed to RSV in 5 cohorts;

-- Escalating viral inoculums were used from log 3 to log 5 plaque forming units (PFU), a measure of viral inoculum concentration;

-- Clinical and virologic signs of infection, e.g., viral load and viral shedding, were documented;

-- 72 percent of subjects were infected with a mean incubation period of 3.2 days, duration of infection of 7 days, and viral load (by an area under the curve analysis) of 61.9 log 10 PFU-days; and,

-- No significant adverse events were observed.

"We are pleased with the progress we have made to date with the clinical development of ALN-RSV01, an RNAi therapeutic for the treatment of RSV," said Akshay Vaishnaw, M.D., Ph.D., Vice President, Clinical Research of Alnylam. "Experimental infection models have been used to develop many anti-viral treatments including those for flu and the common cold, and we believe that such a model is a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 20, 2011 Ann Arbor SPARK recently celebrated the conclusion ... and a reception.  At the Ann Arbor SPARK Boot Camp ... Boot Camp" winner, based on the quality of its investor ... engagement though the Ann Arbor SPARK Business Accelerator.   ...
... HYDERABAD, India, May 20, 2011 Neuland Laboratories Ltd., ... (APIs), complex intermediates, and contract research and manufacturing services ... results for the 2011 fiscal year (FY) ended March ... report that in fiscal year 2011, Neuland delivered on ...
Cached Medicine Technology:Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2Neuland Labs Reports Financial Results for Fiscal Year 2011 2
(Date:7/13/2014)... By Serena Gordon ... -- A new type of sensor for people with ... body using saliva instead of blood, researchers report. Scientists ... successfully tested it using artificial saliva. It uses light, metal ... blood sugar. "Everybody knows that diabetics have to prick ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
(Date:7/13/2014)... July 13, 2014 Recently, MyDressCity.com, one ... women’s special occasion outfits, has released its new range ... the new products are available at discounted prices. Worldwide ... 2014. , In the company’s online shop, there ... of them are made with great materials. MyDressCity.com’s hot ...
(Date:7/13/2014)... A noninvasive optical imaging device developed at Cedars-Sinai ... occur in the brain and are a classic ... from investigators conducting a clinical trial in Australia. ... 15 in an oral presentation at the Alzheimer,s ... also were invited by conference organizers to participate ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... provides concierges companionship that goes beyond caretaking, ... Angel(TM) Inc., a,new company that provides individualized care ... it will launch its most,innovative service for providing ... concierges who will provide engaging one-on-one experiences for,seniors ...
... Celebrate YMCA Healthy Kids Day Saturday, April ... HILL, Calif., April 11 The Mt. Diablo Region,YMCA will ... YMCA,Healthy Kids Day on Saturday, April 12 from 9 a.m. ... and Irvin Deutscher Family YMCA.,An opportunity for kids and families ...
... Call Scheduled for 8:30 a.m. ET, ORANGE COUNTY, ... ) announced today it will host a conference call ... discuss the company,s first,quarter 2008 results. Earnings will be ... The call may be accessed by dialing (877) ...
... least surprised when researchers got paid but more upset ... News) -- Many volunteers in clinical studies aren,t overly ... some loss of trust, suggests a U.S. study. , ... clinical trial did not suffer substantially based on the ...
... NEW YORK, April 11 Takeda,Pharmaceutical Company Limited ... cash tender offer for all outstanding shares of ... for US$25.00 per share. The tender offer is ... subsidiary of Takeda America Holdings,Inc., which is a ...
... was,issued today by the Joint Center for Political ... for Political and Economic Studies in,collaboration with California ... Latino Elected and Appointed Officials (NALEO) will,conduct a ... and Why,They are Integral to Health Equity" during ...
Cached Medicine News:Health News:Send Me An Angel(TM) Pairs Senior Citizens With Their Peers in Alternative Care 2Health News:Send Me An Angel(TM) Pairs Senior Citizens With Their Peers in Alternative Care 3Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 2Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 3Health News:Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens 2Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2Health News:Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium 2Health News:Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium 3Health News:Joint Center to Focus on Issues of Health Equity During Congressional Black Caucus Spring Health Braintrust 2
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
Inquire...
... Immunosorbent Assays(ELISA) is intended for the detection ... Measles Rubeola) virus in human sera. Individual ... determination of immune status. Paired sera, acute ... or a significant rise in antibody as ...
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Medicine Products: